PainReform Ltd. (PRFX)

Overview

PainReform Ltd. is a clinical stage specialty pharmaceutical company primarily engaged in the reformulation of established therapeutics. The company's aim is to offer innovative solutions for the extended relief of post-surgical pain, adopting a focused approach to pain management that caters to the unmet needs of patients recovering from surgeries. Established in 2007 and rooted in Tel Aviv, Israel, PainReform has been advancing its proprietary technologies with the mission to enhance patient recovery experiences by mitigating acute pain following surgical procedures.

Products and Services

• PRF-110 - PainReform's flagship product is PRF-110, which is an oil-based solution designed for direct instillation into surgical wounds. This product represents the core of PainReform's innovative pain management solutions, offering localized and extended post-operative analgesia. PRF-110's formulation allows for a sustained release of the active analgesic agent, ensuring prolonged pain relief which is critical for the initial phases of surgical recovery. Consequently, PRF-110 aims to improve the overall recovery experience for patients by effectively managing post-operative pain.

• Phase 3 Clinical Trials - PainReform is currently conducting Phase 3 clinical trials to evaluate the efficacy and safety of PRF-110 in pain management for patients undergoing specific surgical procedures. The first trial focuses on patients undergoing bunionectomy, a common foot surgery, aiming to provide evidence of PRF-110's analgesic effectiveness in post-operative care. Additionally, a second trial targets the evaluation of PRF-110 in patients undergoing hernia repair operations, addressing another critical area of post-surgical pain management. These trials are pivotal in PainReform's efforts to validate PRF-110's potential in a clinical setting and bring the product closer to market availability, thereby fulfilling the company's mission of alleviating post-surgical pain on a broader scale.